trending Market Intelligence /marketintelligence/en/news-insights/trending/kuuabfgjf2xeew0l57gn9w2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Gene therapy focused Genprex prices IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Gene therapy focused Genprex prices IPO

Genprex Inc. priced its IPO of 1,280,000 common shares at $5 apiece.

Network 1 Financial Securities Inc. is acting as the sole book-running manager for the offering which is expected to close on April 3.

The Austin, Texas-based company, which is developing a therapy for lung cancer, is listing on Nasdaq under the symbol 'GNPX.'

The IPO's underwriters can buy up to an additional 192,000 shares from the company.